Hydromorphonhydrochlorid Beta (Hydromorphone Hydrochloride)

Hydromorphone exerts its effect by binding to mu‑opioid receptors in the brain and spinal cord. This binding activates inhibitory G‑protein pathways, reducing neuronal firing and neurotransmitter release, which raises the pain threshold and produces analgesia and sedation.

The specific dose of hydromorphone is individualized and must be determined by a qualified prescriber based on the patient’s pain severity, prior opioid exposure, age, organ function, and other clinical factors. No fixed dosing regimen is provided here.

Safety data for hydromorphone during pregnancy and lactation are limited. Opioids can cross the placenta and may cause neonatal respiratory depression or withdrawal. Use only if the potential benefit justifies the potential risk, and discuss with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Hydromorphone is roughly five to seven times more potent than morphine on a milligram‑per‑milligram basis, offering stronger analgesia at lower doses. Both act on mu‑opioid receptors, but hydromorphone has a shorter onset and may produce fewer histamine‑related side effects, while morphine is more widely available in injectable form.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and excessive heat. Keep the container tightly closed and out of reach of children and unauthorized personnel.

Hydromorphonhydrochlorid Beta is intended for oral administration. It may be supplied as tablets or oral solution, to be taken with or without food as directed by the prescriber. Swallow tablets whole; do not crush or chew unless specifically instructed.

The most critical risks include respiratory depression, severe hypotension, profound sedation, and the potential for dependence, abuse, or addiction. Patients should be monitored closely for signs of respiratory compromise, especially after dose initiation or dose escalation.

Hydromorphone is contraindicated in patients with known hypersensitivity to hydromorphone or any component of the formulation, in those with severe respiratory depression, acute or severe bronchial asthma, and in individuals who have taken monoamine oxidase inhibitors within the past 14 days.